1. Home
  2. TYRA vs HQH Comparison

TYRA vs HQH Comparison

Compare TYRA & HQH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tyra Biosciences Inc.

TYRA

Tyra Biosciences Inc.

HOLD

Current Price

$26.31

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Logo abrdn Healthcare Investors Shares of Beneficial Interest

HQH

abrdn Healthcare Investors Shares of Beneficial Interest

HOLD

Current Price

$19.00

Market Cap

1.0B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
TYRA
HQH
Founded
2018
1986
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance Companies
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.0B
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
TYRA
HQH
Price
$26.31
$19.00
Analyst Decision
Strong Buy
Analyst Count
6
0
Target Price
$32.17
N/A
AVG Volume (30 Days)
552.8K
183.8K
Earning Date
11-05-2025
01-01-0001
Dividend Yield
N/A
11.56%
EPS Growth
N/A
N/A
EPS
N/A
1.09
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$15.24
Revenue Growth
N/A
N/A
52 Week Low
$6.42
$14.31
52 Week High
$27.66
$17.94

Technical Indicators

Market Signals
Indicator
TYRA
HQH
Relative Strength Index (RSI) 69.02 52.03
Support Level $24.95 $18.39
Resistance Level $27.66 $19.14
Average True Range (ATR) 1.25 0.34
MACD -0.07 -0.03
Stochastic Oscillator 69.41 64.47

Price Performance

Historical Comparison
TYRA
HQH

About TYRA Tyra Biosciences Inc.

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

About HQH abrdn Healthcare Investors Shares of Beneficial Interest

abrdn Healthcare Investors Formerly Tekla Healthcare Investors is the United States based non-diversified closed-end management investment company. Its objective is to seek long-term capital appreciation by investing in securities of healthcare companies. In addition, the fund seeks to provide regular distribution of realized capital gains. The fund invests in the securities of public and private companies.

Share on Social Networks: